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The Financial and Psychosocial Impact of Medicinal Cannabis 
Andrew Lee, Chris Ahmed**, Amanda Campbell, Greg Garber, MSW, LCSW, Neil Palmisiano, 
MD, Brooke Worster, MD* 
 
Introduction: The use of medicinal cannabis for symptom management in cancer patients is a 
growing area of clinical interest. Past studies have demonstrated cannabis’s potential as an 
antiemetic and analgesic, but there is still much research to be done on its clinical efficacy. Our 
study hypothesizes that cancer patients using medicinal cannabis experience subjective 
improvements in pain, chemotherapy-induced nausea and vomiting (CINV), and quality of life 
(QOL) that justify related out-of-pocket costs. 
Methods: Cancer patients are surveyed by phone three to six months after certification for 
access to medicinal cannabis. The survey assesses patient-reported changes in pain, CINV, QOL, 
and financial burden. Patient responses are documented as changes in satisfaction compared to 
baseline satisfaction using a Likert scale (1-5; 1 = greatly decreased satisfaction, 5 = greatly 
increased satisfaction). Aggregate scores over 3.5 indicate meaningful symptomatic 
improvement. 
Results: The initial 35 surveys (desired n = 120) show moderately increased satisfaction with 
CINV and pain relief (3.63 and 3.53, respectively), with mildly increased satisfaction with QOL 
(3.46). Patients report meaningful improvements in nausea, mood, ability to function in daily 
 life, and pain interference with sleep and general activity. Patients generally do not report 
decreased financial satisfaction (3.03). 
Conclusion: Preliminary data suggests that medicinal cannabis may provide analgesic, 
antiemetic, and anxiolytic benefits for cancer patients. If future surveys yield similar results, we 
anticipate that our study could support the use of medicinal cannabis as a cost-effective 
adjunctive therapy for cancer patients suffering treatment or cancer related side effects. 
